Source: Algernon Pharmaceuticals.
  • Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 to complete its planned phase 1 and phase 2 clinical trials
  • Algernon has appointed Dr. Anthony Rudd and Dr. Robert Simister, as medical consultants to the company’s DMT stroke clinical research program
  • Both UK-based doctors have extensive backgrounds in stroke management as well as clinical care and stroke research
  • They will help guide the phase 2 acute stroke and post stroke therapy clinical trials planned to begin in the U.K. following the completion of the phase 1 trial
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.67 per share

Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.

The company believes it has produced a sufficient supply of cGMP DMT to complete its planned phase 1 and phase 2 clinical trials.

Algernon has appointed Dr. Anthony Rudd and Dr. Robert Simister, as medical consultants to the company’s DMT stroke clinical research program. Both Dr. Rudd and Dr. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.

Their primary responsibility will be to help guide the phase 2 acute stroke and post-stroke therapy clinical trials planned to begin in the U.K. in the latter part of 2022 following the completion of the phase 1 trial.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.67 per share.

More From The Market Online

Voyageur Pharmaceuticals signs $2.6M contract in Latin America

Voyageur Pharmaceuticals (TSXV:VM) announces its first international distribution agreement with a C$2.6 million commitment.
BriaCell Therapeutics Corp

BriaCell to report positive cancer research at medical convention

BriaCell Therapeutics (TSX:BCT) will present positive clinical data of Bria-IMT at the 2024 American Society of Clinical Oncology in Chicago.

Cloud DX among leading remote patient monitoring suppliers in Canada

Cloud DX (TSXV:CDX) gives an update on its remote patient monitoring deal with the British Columbia Provincial Health Services Authority.